Ramot B, Ben-Bassat I
Bull World Health Organ. 1979;57(6):857-63.
The recent developments and results of treatment in Hodgkin's disease suggest that staging laparotomy is indicated in certain selected groups of patients and should not be performed routinely in patients whose therapy is unlikely to be changed by the findings.Early stage nodal Hodgkin's disease is best treated by extended radiotherapy. The exact role of adjuvant chemotherapy is not settled, but there are certain groups of high-risk patients who should receive chemotherapy, such as those with extensive mediastinal disease or advanced IIIA patients. In the advanced stages, chemotherapy assumes the primary role and with the MOPP programme (chlormethine, vincristine, procarbazine, and prednisone), alone or alternating with ABVD (doxorubicin, bleomycin, vinblastine, and imidazole carboxamide), a substantial number of patients can be controlled or cured.The therapeutic approach to non-Hodgkin's lymphoma should be guided mainly by the histological findings, favourable or unfavourable, and to a lesser degree also by the stage of the disease. In these patients, chemotherapy rather than radiotherapy is the treatment of choice. In the favourable histology group, a conservative approach is usually justified in the majority of patients, while in the unfavourable histology group, aggressive combination chemotherapy containing adriamycin is the recommended therapy.In underprivileged populations, the abdominal and intestinal localization of lymphomas is more common than in Europe and North America. Two lymphomas of special interest are Burkitt's lymphoma and intestinal lymphoma in their varying aspects. In both diseases, the importance of environmental factors is highly suggestive. Referral of such patients to centres involved in the management of these diseases is essential.
霍奇金病的近期治疗进展和结果表明，分期剖腹术适用于某些特定选择的患者群体，而对于那些其治疗不太可能因检查结果而改变的患者，不应常规进行。早期淋巴结霍奇金病最好采用扩大放疗。辅助化疗的确切作用尚未确定，但有某些高危患者群体应接受化疗，例如那些有广泛纵隔疾病的患者或晚期IIIA期患者。在晚期，化疗起主要作用，采用MOPP方案（氮芥、长春新碱、丙卡巴肼和泼尼松），单独使用或与ABVD方案（阿霉素、博来霉素、长春花碱和甲氮咪胺）交替使用，大量患者可以得到控制或治愈。非霍奇金淋巴瘤的治疗方法应主要根据组织学结果（有利或不利）来指导，在较小程度上也根据疾病分期来指导。在这些患者中，化疗而非放疗是首选治疗方法。在组织学表现有利的组中，大多数患者通常采用保守方法是合理的，而在组织学表现不利的组中，推荐采用含阿霉素的积极联合化疗。在贫困人群中，淋巴瘤的腹部和肠道定位比在欧洲和北美更为常见。特别值得关注的两种淋巴瘤是伯基特淋巴瘤和不同表现形式的肠道淋巴瘤。在这两种疾病中，环境因素的重要性都极具暗示性。将此类患者转诊至参与这些疾病管理的中心至关重要。
